Cargando…

The present and future of measurable residual disease testing in acute myeloid leukemia

Considerable progress has been made in the past several years in the scientific understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement of a conventional remission, evaluated cytomorphologically via small bone marrow samples, is a necessary but not sufficient step t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blachly, James S., Walter, Roland B., Hourigan, Christopher S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Review Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713561/ https://www.ncbi.nlm.nih.gov/pubmed/36453518 http://dx.doi.org/10.3324/haematol.2022.282034

Ejemplares similares

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia
por: Dillon, Laura W., et al.
Publicado: (2019)

Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
por: Saygin, Caner, et al.
Publicado: (2022)

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
por: Yoest, Jennifer M., et al.
Publicado: (2020)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Hidradenitis suppurativa in acute myeloid leukemia: Review of disease course and management
por: Chen, Stella X., et al.
Publicado: (2021)

Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia
por: Kim, Seon Young, et al.
Publicado: (2023)

Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study
por: Scott, Stuart, et al.
Publicado: (2023)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
por: Azenkot, Tali, et al.
Publicado: (2022)

Improved detection of measurable residual disease in acute myeloid leukemia
por: Zhang, Xuan, et al.
Publicado: (2023)

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
por: Shih, Lauren, et al.
Publicado: (2023)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
por: Li, Xueyao, et al.
Publicado: (2023)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Pediatric Acute Myeloid Leukemia—Past, Present, and Future
por: Reinhardt, Dirk, et al.
Publicado: (2022)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
por: Božić, Tanja, et al.
Publicado: (2021)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2023)

Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review
por: Kim, Sang-A, et al.
Publicado: (2022)

Present and Future Role of Immune Targets in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2022)

3q26 chromosomal anomalies in acute myeloid leukemia: First descriptions from India
por: Gupta, A, et al.
Publicado: (2018)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
por: Buccisano, Francesco, et al.
Publicado: (2018)

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia
por: Fang, Qiuyun, et al.
Publicado: (2022)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
por: Röhnert, Maximilian A., et al.
Publicado: (2022)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
por: Bocchia, Monica, et al.
Publicado: (2022)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges
por: Schlenk, Richard F.
Publicado: (2023)

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
por: Short, Nicholas J., et al.
Publicado: (2019)

Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: Pan, Jonathan, et al.
Publicado: (2020)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
por: Patkar, Nikhil, et al.
Publicado: (2019)

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
por: Pratz, Keith W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ci0i0oi35dplj6dl645iplteg